Innerbody Labs Testosterone Support Announces Official Website Update Featuring Natural Daily Supplement for Men's Health and Vitality
PALO ALTO, June 09, 2025 (GLOBE NEWSWIRE) —
Innerbody Testosterone Support, a California-based wellness brand developed by Innerbody Research, Inc., has updated its official website to highlight a daily supplement designed to support testosterone health, energy, and physical performance in adult men. Available nationwide, the formula is intended for individuals seeking a natural, consistent addition to their wellness routines.
According to the official product page (https://shop.innerbody.com/products/testosterone-support), Innerbody Testosterone Support works in concert with the body's internal systems to help maintain healthy testosterone levels associated with vitality, stamina, and overall wellness. The product is positioned as a clean, once-daily supplement made for modern lifestyles—no complicated regimens or restrictive dietary requirements.
'We believe that supporting your health should be simple, effective, and transparent,' said a company representative. 'Our testosterone support formula reflects that philosophy and our commitment to natural wellness backed by science.'
Innerbody Research, Inc. confirms that its supplements are manufactured in facilities following rigorous quality assurance protocols. The product is composed of carefully selected ingredients that align with common goals for adult male wellness, such as hormone balance, muscle support, and natural energy maintenance.
As shared on the website, the product includes a satisfaction guarantee for new customers. Additional product details, usage insights, and ordering options are available at the official site.
About Innerbody Testosterone Support
Innerbody Testosterone Support is part of Innerbody Research, Inc., a wellness brand based in Palo Alto, California, focused on delivering research-informed supplements that promote health and longevity. The brand emphasizes transparency, natural formulation, and ease of use to help adults support their wellness goals through daily routines.
Product and Contact Information
Brand: Innerbody Testosterone Support
Website: https://shop.innerbody.com/products/testosterone-support
Email: [email protected]
Phone: +1 (650) 456-2677
Mailing Address: Innerbody Research, Inc.3790 El Camino Real, Unit 524
Palo Alto, CA 94306
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
SRx Health Solutions Announces Management and Board Changes
TAMPA, Fla., June 11, 2025 (GLOBE NEWSWIRE) -- SRx Health Solutions, Inc. (NYSE American: SRXH) (the 'Company'), a leading global health and wellness company, today announced the following management team and Board of Directors changes. Lionel Conacher, current Board member, has been appointed as Chairman of the Board, Adesh Vora, current Executive Chairman, will remain on Board and be appointed Chief Executive Officer, Kent Cunningham, current Chief Executive Officer, will assume role as President, and Nina Martinez has been appointed Chief Financial Officer. Adesh Vora, Chief Executive Officer of SRx Health Solutions, stated, 'We are grateful to our Board and senior management for their efforts in strengthening our team structure and enhancing corporate governance. These improvements align with our renewed vision for SRx Health's long-term strategic growth. Looking ahead, our core focus will be on supporting patients managing chronic and rare diseases, infusion services, clinical trials, and patient support programs to make healthcare simpler for our customers. At the same time, we will continue to build on our values—partnering with patients, pharmaceutical manufacturers, and prescriber relations.' About SRx Health Solutions, Inc. SRx Health Solutions Inc. is an integrated Canadian healthcare services provider that operates within the specialty healthcare industry. The SRx network extends across all ten Canadian provinces, making it one of the most accessible providers of comprehensive, integrated, and customized specialty healthcare services in the country. SRx combines years of industry knowledge, technology, and patient-centric focus to create strategies and solutions that consistently exceed client expectations and drive critical patient care initiatives aimed to improve the wellness of Canadians. For more information on SRx Health Solutions Inc., please visit Forward Looking StatementsThis press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The words 'believe,' 'may,' 'estimate,' 'continue,' 'anticipate,' 'intend,' 'should,' 'plan,' 'could,' 'target,' 'potential,' 'is likely,' 'will,' 'expect' and similar expressions, as they relate to us, are intended to identify forward-looking statements. The Company has based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our financial condition, results of operations, business strategy and financial needs. Some or all of the results anticipated by these forward-looking statements may not be achieved. Further information on the Company's risk factors is contained in our filings with the SEC. Any forward-looking statement made by us herein speaks only as of the date on which it is made. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by law. Company Contact:SRx Health Solutions, A. Vora, Chief Executive Officer Investor Contact:KCSA Strategic CommunicationsValter Pinto, Managing DirectorT: 212-896-1254Valter@
Yahoo
2 hours ago
- Yahoo
Texas to expand psychedelic research with $50M ibogaine investment
AUSTIN (KXAN) — Texas Gov. Greg Abbott is holding a bill signing ceremony Tuesday for legislation that invests $50 million into clinical research of ibogaine — a naturally occurring psychedelic substance that could treat post-traumatic stress disorder, opioid use disorder and other mental health conditions. For years, veterans and others suffering from PTSD have sought ibogaine treatment in Mexico, where the substance is not heavily regulated. In the United States, ibogaine is classified as a Schedule 1 drug, the most restrictive drug category. Other drugs classified under Schedule 1 include psilocybin, LSD and heroin. According to the legislative summary of SB 2308, the implications for those with opioid use disorder are lifechanging; a single administration of ibogaine in a controlled setting has been shown to stop withdrawal symptoms and reduce drug cravings long-term. RELATED: Lawmakers hope to expand medical marijuana program as state bans intoxicating hemp products 'Preliminary reports also suggest benefits in cognitive function, mood regulation, and sleep among individuals with [traumatic brain injury] and PTSD—conditions prevalent among U.S. veterans,' the bill text read. The new legislation will create a program within the Texas Health and Human Services Commission to support Texas-based trials of ibogaine through the FDA. Ibogaine is not currently FDA-approved due to its Schedule 1 classification. SB 2308 will fund research through gifts, grants or donations and will require equal matching funds by the recipients, which will include Texas medical facilities 'equipped for cardiac-intensive monitoring' by a supervising physician, among other qualifications. 'By advancing ibogaine research, Texas has the opportunity to lead in neuroscience innovation, address urgent veteran health needs, and shape the future of mental health treatment nationwide,' the bill text reads. While legislation aimed at easing access to ibogaine moves forward, separate legislation to restrict access to another plant has also progressed. Texas lawmakers sent a bill banning non-medical THC products to Abbott for approval late last month. Still, Texas in recent years has become more open-minded to the use of psychedelic substances in treating mental health conditions. 'There's definitely been a shift in the openness and the receptivity of the field to this type of research,' said Greg Fonzo, Ph.D., co-director of the McGill Center for Psychedelic Research & Therapy at Dell Medical School. 'People who do undergo this treatment process, some of them respond well and have a benefit in terms of symptom reductions and feeling better,' Fonzo told KXAN earlier this year. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Yahoo
2 hours ago
- Yahoo
Jim Cramer on Cardinal Health: 'I am a Believer'
Cardinal Health, Inc. (NYSE:CAH) is one of the 11 stocks on Jim Cramer's radar. Calling Cardinal Health, Inc.'s (NYSE:CAH) upcoming Investor Day a possible needle mover, Cramer said: 'Now, Thursday brings some analyst meetings that could move the needle. Cardinal Health, we've had them on a couple of times, tells a terrific story about how it's much more than a drug middleman. And I believe, I am a believer.' A senior physician in a modern healthcare institution administering medication to a patient. Cardinal Health (NYSE:CAH) provides medical products and services used in various care settings. The company delivers pharmaceuticals, equipment, and support tools while managing distribution, logistics, and pharmacy operations through healthcare-focused technology. On May 14, Cramer extensively commented on the company as he said: 'These stocks, namely Cardinal Health, Cencora, and McKesson, are seemingly perpetual residents on the new high list. Over the long haul, they're some of the best performers out there, and they've done great this year, as is pretty much always the case. And yet, doesn't it always feel like the drug distributors are just one bad day away from falling apart… Let's not forget that the drug distributors are making fortunes right now. Cardinal Health turned in an excellent set of numbers two weeks ago with double-digit earnings growth. Management put through a big boost in their full-year earnings forecast. Cardinal stock jumped 3% in response, climbing from $141 to $145, and it kept running for really a week after that, eventually setting at an all-time high of $154 just last Thursday. What a fabulous move… While we acknowledge the potential of CAH as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
